NewAmsterdam Pharma's Insights at the Virtual Cardiometabolic Forum

Author: Olivia Taylor Updated: 09-24-2025 08:35 AM

NewAmsterdam Pharma's Upcoming Presentation

NewAmsterdam Pharma Company N.V. (NASDAQ: NAMS) is gearing up for an exciting participation at the renowned Stifel 2025 Virtual Cardiometabolic Forum. The company, well-regarded for its late-stage development of oral non-statin medicines for cardiovascular disease (CVD), is set to feature prominently in discussions aimed at improving patient care and addressing significant medical needs.

Engagement of Key Executives

During the forum, scheduled for a future date, the spotlight will be on John Kastelein, the Chief Scientific Officer, and Matthew Philippe, the Executive Vice President, who will engage the audience in a virtual fireside chat. Their insights are expected to provide valuable perspectives on the innovative work being done at NewAmsterdam, specifically in the realm of treating patients with elevated low-density lipoprotein cholesterol (LDL-C).

Live Webcast Experience

For those interested in learning more about NewAmsterdam's advancements, the company will make a live webcast available through their investor relations section. Following the chat, an archived replay can also be accessed on their official website, ensuring broader reach and engagement with stakeholders and the public alike.

The Mission of NewAmsterdam Pharma

At the heart of NewAmsterdam's mission lies a commitment to enhance patient lives, particularly in populations battling metabolic diseases where existing therapies have fallen short. The company aims to provide a safe, well-tolerated, and practical LDL-lowering therapy, addressing a significant gap in treatment options currently available.

Clinical Trials and Innovations

In multiple Phase 3 trials, NewAmsterdam is investigating obicetrapib, an oral, low-dose CETP inhibitor aimed at reducing LDL-C levels among those at risk of CVD. This treatment is being studied both individually and as a fixed-dose combination with ezetimibe, offering promising results for patients who are not achieving desired outcomes with existing therapies.

Company Contact Information

For inquiries, Matthew Philippe is available at 1-917-882-7512 or via email at matthew.philippe@newamsterdampharma.com. Interested parties can also reach out to the media contact, Christian Edgington at Real Chemistry, at 1-513-310-6410 or at cedgington@realchemistry.com.

Frequently Asked Questions

What is the focus of NewAmsterdam Pharma?

NewAmsterdam Pharma focuses on developing innovative oral medications for lowering cholesterol in patients at risk of cardiovascular disease.

Who will be speaking at the Stifel 2025 Virtual Cardiometabolic Forum?

John Kastelein, Chief Scientific Officer, and Matthew Philippe, Executive Vice President, will represent NewAmsterdam Pharma during the event.

How can I watch the live presentation?

The presentation will be available via a live webcast through the investor relations section of NewAmsterdam's official website.

What is obicetrapib?

Obicetrapib is an experimental therapy being investigated by NewAmsterdam as a treatment option for lowering LDL cholesterol in patients with cardiovascular risks.

How can I contact NewAmsterdam Pharma?

You can contact Matthew Philippe at 1-917-882-7512 or via email at matthew.philippe@newamsterdampharma.com.

About The Author

Olivia Taylor here, a 26-year-old writer and financial advisor. After earning a degree in finance, I worked in the sector for years. I've always loved numbers and had a talent for simplifying difficult financial ideas so that anyone could understand. I wrote my first book because of this passion; it helps readers take charge of their financial futures by fusing real-life stories with useful financial advice.

Whether they are just beginning their careers, preparing for significant life events, or seeking to invest wisely, my goal with my writing is to enable people to make educated financial decisions. The foundation of my work is the conviction that security and freedom of the individual are largely determined by financial literacy. To further financial education, I run workshops and frequently write for financial blogs in addition to my books.

I like to travel, experience other cultures, and find inspiration in daily life when I'm not writing or examining market trends. My passion is utilizing sound financial practices to help people reach their financial objectives and lead the best lives possible.

Contact Olivia Taylor privately here. Or send an email with ATTN: Olivia Taylor as the subject to contact@investorshangout.com.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.